Sertraline
Small molecule targets SLC6A4 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 12 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (11) | US (FDA) | ZOLOFT | — | 1996-10-25 – 2004-08-19 | fda.gov ↗ |
| Approved | US (FDA) | ZOLOFT | — | 1991-12-30 | fda.gov ↗ |
Trials 186 · started per year
Also used as a comparator or background therapy in 154 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT06965569 Background | Apr → Dec 2025 | — | Alar Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03514810 Background | Jan → Sep 2017 | major depressive disorder | Kufa University | Completed | No outcome recorded |
| Phase 1 | NCT03469128 Comparator | Jan 2016 → Jan 2020 | — | British University In Egypt | Completed | No outcome recorded |
| Phase 1 | NCT01347541 Background | Jan → Nov 2011 | post-traumatic stress disorder | University of Washington | Terminated | No outcome recorded |
| Phase 1 | NCT01235195 Comparator | Nov → Dec 2010 | — | Viatris Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00208117 Comparator | Apr 2005 → Jan 2009 | acute coronary syndrome, coronary artery disorder, depressive disorder | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT02917122 Comparator | Aug 2015 → Aug 2021 | Parkinson disease, depressive disorder | National Cheng-Kung University Hospital | Terminated | No outcome recorded |
| Phase 1/2 | NCT00612807 Background | Jul 2006 → Jun 2010 | major depressive disorder | Duke University | Completed | No outcome recorded |
| Phase 223 trials | ||||||
| Phase 2 | NCT07539805 Background | Jun 2026 → Feb 2028 expected | major depressive disorder | First Affiliated Hospital of Chongqing Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06408246 Background | Mar 2026 → Oct 2028 expected | depressive disorder | Stanford University | Recruiting | No outcome recorded |
| Phase 2 | NCT06081348 Comparator | Sep 2024 → Sep 2026 expected | Tourette syndrome, anxiety, attention deficit hyperactivity disorder, inattentive type, autism +3 | Holland Bloorview Kids Rehabilitation Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05646693 Background | Dec 2022 → Dec 2023 | tinnitus | University of Guadalajara | Unknown | No outcome recorded |
| Phase 2 | NCT04539951 Comparator | Sep 2020 → Jun 2027 expected | obsessive-compulsive disorder | Shanghai Mental Health Center | Recruiting | No outcome recorded |
| Phase 2 | NCT03321526 Background | Dec 2017 → Jun 2019 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 2 | NCT03279471 Comparator | Oct 2017 → Feb 2023 | anxiety, autism spectrum disorder | University of California, Davis | Completed | No outcome recorded |
| Phase 2 | NCT04637620 Comparator | Jun 2017 → Nov 2026 expected | major depressive disorder | China Medical University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT03414931 Comparator | Jan 2016 → Nov 2020 | major depressive disorder | Chang Gung Memorial Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02385799 Comparator | Apr 2015 → Jul 2018 | autism spectrum disorder | Randi J. Hagerman, MD | Completed | No outcome recorded |
| Phase 2 | NCT02469545 Comparator | Jun 2014 → Mar 2016 | anxiety disorder, major depressive disorder | Medical University of Bialystok | Completed | No outcome recorded |
| Phase 2 | NCT02021669 Background | May 2014 → Sep 2018 | depressive disorder | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT01769027 Comparator | Jun → Dec 2013 | — | CNS Onlus | Withdrawn | No outcome recorded |
| Phase 2 | NCT01703039 Background | Jan 2013 → Jun 2018 | major depressive disorder | Brigham and Women's Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT01407094 Comparator | Jul 2011 → Apr 2016 | depressive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01254305 Comparator | Apr 2011 → Jul 2012 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 2 | NCT00854100 Background | Jun 2009 → Dec 2010 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 2 | NCT00797966 Background | May 2009 → Jun 2010 | major depressive disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00602355 Comparator | Feb 2008 → Jul 2014 | postpartum depression | Women and Infants Hospital of Rhode Island | Completed | No outcome recorded |
| Phase 2 | NCT00262223 Comparator | May 2006 → Jul 2013 | alcohol abuse, post-traumatic stress disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase 2 | NCT00232284 Comparator | Sep 2004 → May 2009 | depressive disorder, substance-related disorder | Dan Lubman | Completed | No outcome recorded |
| Phase 2 | NCT00636246 Comparator | Jun 2004 → Aug 2005 | major depressive disorder | Viatris Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00249431 Comparator | Dec 2001 → Dec 2005 | alcohol dependence, pathological gambling | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT07574060 Comparator | May 2026 → May 2027 expected | major depressive disorder | Tanta University | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT02565316 Comparator | Nov 2014 → Mar 2015 | anxiety, depressive disorder | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT00299611 Comparator | Nov 2005 → Dec 2007 | obsessive-compulsive disorder | Duke University | Terminated | No outcome recorded |
| Phase 2/3 | NCT00215241 Background | Apr 2004 → Jul 2006 | post-traumatic stress disorder | Duke University | Completed | No outcome recorded |
| Phase 2/3 | NCT00340379 Comparator | Apr 2003 → Aug 2005 | mood disorder | Duke University | Completed | No outcome recorded |
| Phase 339 trials | ||||||
| Phase 3 | NCT06827431 Comparator | Feb 2025 → Jun 2026 overdue | major depressive disorder | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06025474 Comparator | Jan → Oct 2023 | burning mouth syndrome | Federico II University | Unknown | No outcome recorded |
| Phase 3 | NCT06698666 Background | Oct 2022 → Dec 2024 overdue | major depressive disorder | Ain Shams University | Recruiting | No outcome recorded |
| Phase 3 | NCT04598230 Comparator | Feb 2021 → Aug 2025 overdue | generalized anxiety disorder, separation anxiety disorder, social phobia | Ann & Robert H Lurie Children's Hospital of Chicago | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04476030 Background | Nov 2020 → Oct 2021 | major depressive disorder | Biogen | Completed | No outcome recorded |
| Phase 3 | NCT03852160 Background | Dec 2019 → Jul 2021 | major depressive disorder | Janssen-Cilag International NV | Withdrawn | No outcome recorded |
| Phase 3 | NCT03538691 Background | Jul 2018 → Jul 2022 | major depressive disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03434041 Background | May 2018 → Apr 2021 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02493868 Background | Oct 2015 → Feb 2018 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02497287 Background | Sep 2015 → Oct 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02422186 Background | Aug 2015 → Aug 2017 | major depressive disorder | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02417064 Background | Aug 2015 → Feb 2018 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02418585 Background | Aug 2015 → Jun 2017 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 3 | NCT02358343 Comparator | Mar 2015 → Nov 2017 | depressive disorder, end stage renal failure | University of Washington | Completed | No outcome recorded |
| Phase 3 | NCT02400346 Background | Mar 2015 → Jun 2016 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT02279953 Background | Oct 2014 → Apr 2016 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT02046564 Background | Feb 2014 → Sep 2016 | major depressive disorder | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01838681 Background | Jun 2013 → Jun 2016 | major depressive disorder | H. Lundbeck A/S | Completed | No outcome recorded |
| Phase 3 | NCT01838876 Background | Apr 2013 → Jul 2015 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT01715805 Background | Nov 2012 → Jun 2016 | major depressive disorder | Forest Laboratories | Completed | No outcome recorded |
| Phase 3 | NCT02179268 Comparator | Mar 2012 → Apr 2014 | osteoporosis | Guiyang Medical University | Completed | No outcome recorded |
| Phase 3 | NCT01436175 Background | Feb 2012 → Mar 2014 | major depressive disorder | Shire | Terminated | No outcome recorded |
| Phase 3 | NCT01436162 Background | Oct 2011 → Dec 2013 | major depressive disorder | Shire | Completed | No outcome recorded |
| Phase 3 | NCT01360866 Background | Oct 2011 → Apr 2017 | major depressive disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01098318 Comparator | Jun 2010 → Jul 2013 | depressive disorder | University of Pennsylvania | Completed | No outcome recorded |
| Phase 3 | NCT00946998 Comparator | Feb 2010 → Nov 2016 | chronic kidney disease, major depressive disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 3 | NCT00857584 Comparator | May 2009 → Feb 2011 | bipolar depression | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00302068 Comparator | Jul 2006 → Jul 2011 | depressive disorder, heart disorder | Duke University | Completed | No outcome recorded |
| Phase 3 | NCT00351910 Background | May 2006 → Apr 2007 | major depressive disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00232167 Background | Nov 2005 → Apr 2006 | insomnia, major depressive disorder | Neurocrine Biosciences | Terminated | No outcome recorded |
| Phase 3 | NCT00116857 Comparator | Feb 2005 → Jun 2009 | depressive disorder, intermediate coronary syndrome, myocardial infarction | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 3 | NCT00127673 Comparator | Sep 2004 → Aug 2011 | post-traumatic stress disorder | Case Western Reserve University | Completed | No outcome recorded |
| Phase 3 | NCT00066859 Comparator | Mar 2004 → Apr 2005 | depressive disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00074815 Background | Sep 2003 → Nov 2009 | obsessive-compulsive disorder | Duke University | Completed | No outcome recorded |
| Phase 3 | NCT00052078 Comparator | Jan 2003 → Oct 2007 | generalized anxiety disorder, social phobia | Johns Hopkins University | Completed | No outcome recorded |
| Phase 3 | NCT00056472 Comparator | Jan 2003 → Jun 2008 | major depressive disorder | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 3 | NCT00158990 Background | Oct 2002 → Jul 2007 | bipolar disorder, major depressive disorder | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase 3 | NCT02122393 Comparator | Apr 2002 → Apr 2005 | anxiety, depressive disorder | University of Melbourne | Completed | No outcome recorded |
| Phase 3 | NCT00026637 Comparator | Aug 2001 → Jun 2007 | depressive disorder, epilepsy | Columbia University | Completed | No outcome recorded |
| Phase 445 trials | ||||||
| Phase 4 | NCT06704594 Comparator | May 2025 → Jul 2029 expected | premenstrual dysphoric disorder | Johns Hopkins University | Recruiting | No outcome recorded |
| Phase 4 | NCT07478796 Comparator | Apr 2025 → Nov 2027 expected | major depressive disorder | Poznan University of Medical Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT07192367 Comparator | Nov 2024 → Aug 2026 overdue | social phobia | Emine Kanmaz | Recruiting | No outcome recorded |
| Phase 4 | NCT05273996 Background | Sep 2021 → Apr 2027 expected | major depressive disorder, neurotic disorder | David Steffens | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04597190 Comparator | Jun 2020 → Aug 2024 | post-traumatic stress disorder | University of Washington | Completed | No outcome recorded |
| Phase 4 | NCT04963257 Background | Jan 2020 → Dec 2023 | obsessive-compulsive disorder | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT05148169 Background | Jan 2020 → Dec 2022 | major depressive disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT04094870 Comparator | Oct 2019 → Oct 2020 | HIV infectious disease, postpartum depression | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 4 | NCT04183205 Comparator | Sep 2019 → Mar 2025 | major depressive disorder, post-traumatic stress disorder | VA Office of Research and Development | Terminated | No outcome recorded |
| Phase 4 | NCT03779789 Comparator | Feb 2019 → Feb 2023 | major depressive disorder | Azienda Ospedaliera Universitaria Integrata Verona | Completed | No outcome recorded |
| Phase 4 | NCT02641652 Comparator | Nov 2017 → Jun 2018 | hypertensive disorder | University Hospital Olomouc | Unknown | No outcome recorded |
| Phase 4 | NCT02137369 Comparator | Sep 2014 → Oct 2019 | major depressive disorder | Emory University | Completed | No outcome recorded |
| Phase 4 | NCT02347033 Comparator | Aug 2014 → Feb 2016 | generalized anxiety disorder | University College, London | Terminated | No outcome recorded |
| Phase 4 | NCT02022709 Comparator | Jan 2014 → Nov 2017 | obsessive-compulsive disorder | Shanghai Mental Health Center | Completed | No outcome recorded |
| Phase 4 | NCT01903447 Comparator | Dec 2013 → Feb 2018 | anxiety | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 4 | NCT01856127 Comparator | Jan 2013 → Jun 2016 | major depressive disorder, sexual disorder | Thomas Jefferson University | Terminated | No outcome recorded |
| Phase 4 | NCT01764867 Comparator | Jun 2012 → Oct 2014 | major depressive disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| Phase 4 | NCT01569685 Comparator | Apr 2012 → Oct 2014 | depressive disorder, post-traumatic stress disorder | Charlotte Sonne | Completed | No outcome recorded |
| Phase 4 | NCT01460212 Comparator | Dec 2011 → Dec 2014 | major depressive disorder | Nanjing Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT01524133 Comparator | Nov 2011 → Dec 2016 | post-traumatic stress disorder | VA Ann Arbor Healthcare System | Completed | No outcome recorded |
| Phase 4 | NCT01427608 Comparator | Oct 2011 → Nov 2017 | psychotic disorder | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT01357967 Comparator | May 2011 → Dec 2012 | major depressive disorder | Inje University | Unknown | No outcome recorded |
| Phase 4 | NCT02178696 Background | Jan 2011 → Oct 2015 | depressive disorder | University of Michigan | Completed | No outcome recorded |
| Phase 4 | NCT01109693 Comparator | Dec 2010 → Sep 2015 | major depressive disorder | Kyoto University | Completed | No outcome recorded |
| Phase 4 | NCT01309074 Comparator | Nov 2009 → Dec 2012 | anxiety, epilepsy | Rush University Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT01305707 Comparator | Jul 2009 → Jul 2014 | major depressive disorder | Hospital Universitari de Bellvitge | Terminated | No outcome recorded |
| Phase 4 | NCT00835627 Comparator | Sep 2008 → Dec 2012 | conversion disorder, depressive disorder, dissociative disorder, post-traumatic stress disorder | Rhode Island Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00955474 Comparator | Sep 2008 → Jan 2013 | major depressive disorder | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00693849 Comparator | Sep 2008 → Dec 2019 | major depressive disorder | BRC Operations Pty. Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT00594269 Comparator | Aug 2008 → Dec 2010 | dementia | Innlandet Hospital Trust | Completed | No outcome recorded |
| Phase 4 | NCT00744328 Comparator | Aug 2008 → Sep 2013 | postpartum depression | Northwestern University | Terminated | No outcome recorded |
| Phase 4 | NCT00666757 Comparator | May 2008 → Feb 2009 | depressive disorder | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 4 | NCT00834652 Background | Sep 2007 → May 2013 | depressive disorder | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 4 | NCT00519012 Comparator | Aug 2007 → Dec 2010 | depressive disorder | Oizumi Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00624013 Comparator | Sep 2006 → Oct 2008 | depressive disorder, diabetes mellitus | Charles Drew University of Medicine and Science | Completed | No outcome recorded |
| Phase 4 | NCT00282828 Background | Mar 2006 → Dec 2011 | social phobia | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00680602 Comparator | Jan 2006 → Sep 2008 | obsessive-compulsive disorder | University of Sao Paulo | Completed | No outcome recorded |
| Phase 4 | NCT00391430 Comparator | May 2005 → Jul 2009 | post-traumatic stress disorder | NYU Langone Health | Terminated | No outcome recorded |
| Phase 4 | NCT00375843 Comparator | Jan 2005 → Jun 2007 | depressive disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 4 | NCT00177424 Comparator | Jul 2004 → Oct 2007 | depressive disorder, stroke disorder | University of Pittsburgh | Terminated | No outcome recorded |
| Phase 4 | NCT00198094 Background | Dec 2003 → Sep 2007 | panic disorder | Indiana University | Completed | No outcome recorded |
| Phase 4 | NCT00159965 Comparator | Dec 2003 → Jun 2008 | conversion disorder, depressive disorder, post-traumatic stress disorder | Rhode Island Hospital | Completed | No outcome recorded |
| Phase 4 | NCT00177996 Comparator | Oct 2001 → Jan 2007 | major depressive disorder | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT01114100 Comparator | Jan 2000 → Dec 2002 | depressive disorder, panic disorder | Maastricht University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00000378 Comparator | Jul 1997 → Jun 2002 | major depressive disorder, melancholia | New York State Psychiatric Institute | Completed | No outcome recorded |
| Phase not applicable34 trials | ||||||
| — | NCT07318181 Comparator | Jan 2026 → Nov 2027 expected | post-traumatic stress disorder | University of Luxembourg | Recruiting | No outcome recorded |
| — | NCT06955845 Comparator | May → Nov 2025 | post-traumatic stress disorder | Asad Ullah Jan | Completed | No outcome recorded |
| — | NCT06957223 Comparator | May → Nov 2025 | major depressive disorder | Asad Ullah Jan | Completed | No outcome recorded |
| — | NCT06942494 Comparator | Apr 2025 → Aug 2027 expected | obsessive-compulsive disorder | Shanghai Mental Health Center | Recruiting | No outcome recorded |
| — | NCT07025590 Comparator | Apr 2025 → Dec 2026 expected | cardiovascular disorder, mixed anxiety and depressive disorder | Guangdong Provincial People's Hospital | Recruiting | No outcome recorded |
| — | NCT06467474 Background | Mar 2024 → Jun 2025 overdue | major depressive disorder | Ricardo Alberto Moreno, M.D., Ph.D. | Recruiting | No outcome recorded |
| — | NCT06659094 Background | Aug 2023 → Aug 2025 | obsessive-compulsive disorder | Shanghai Mental Health Center | Completed | No outcome recorded |
| — | NCT06358014 Background | May 2023 → Dec 2024 | depressive disorder | Xiao Wang | Unknown | No outcome recorded |
| — | NCT05832619 Background | Nov 2022 → Dec 2025 | major depressive disorder | Xiaomei Shao | Unknown | No outcome recorded |
| — | NCT05720637 Background | Nov 2022 → Jan 2024 | major depressive disorder | Xiaomei Shao | Completed | No outcome recorded |
| — | NCT05528224 Background | Sep 2022 → Aug 2023 | obsessive-compulsive disorder | Shanghai Mental Health Center | Terminated | No outcome recorded |
| — | NCT05605002 Background | Jan 2022 → Dec 2025 | major depressive disorder | Xiaomei Shao | Unknown | No outcome recorded |
| — | NCT05588102 Background | May 2021 → May 2023 | cognitive disorder | Capital Medical University | Completed | No outcome recorded |
| — | NCT03179839 Comparator | Jan 2017 → Nov 2018 | obsessive-compulsive disorder | Shanghai Mental Health Center | Completed | No outcome recorded |
| — | NCT02813447 Comparator | Aug 2016 → Feb 2019 | anxiety, chronic obstructive pulmonary disease, depressive disorder, interstitial lung disease | Duke University | Terminated | No outcome recorded |
| — | NCT03558256 Background | May 2016 → Dec 2018 | major depressive disorder | Shanghai Mental Health Center | Unknown | No outcome recorded |
| — | NCT02655354 Background | Oct 2015 → Nov 2019 | alcohol-related disorders, brain injury, cognitive impairment with or without cerebellar ataxia, depressive disorder +1 | University of Washington | Completed | No outcome recorded |
| — | NCT02262156 Comparator | Aug → Oct 2014 | depressive disorder, temporal lobe epilepsy | El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez | Completed | No outcome recorded |
| — | NCT02189213 Comparator | Jul 2014 → Dec 2019 | generalized anxiety disorder, separation anxiety disorder, social phobia | New York State Psychiatric Institute | Terminated | No outcome recorded |
| — | NCT02739061 Comparator | Jun 2014 → Mar 2017 | obsessive-compulsive disorder | Shanghai Mental Health Center | Completed | No outcome recorded |
| — | NCT01943435 Comparator | Nov 2013 → Jun 2016 | lumbar spinal stenosis | Michael Schneider, DC, PhD | Completed | No outcome recorded |
| — | NCT01944657 Comparator | Sep 2013 → Dec 2015 | major depressive disorder | Sheppard Pratt Health System | Withdrawn | No outcome recorded |
| — | NCT01896349 Background | Apr 2013 → Aug 2014 | — | Hospital de Clinicas de Porto Alegre | Unknown | No outcome recorded |
| — | NCT01962753 Background | May 2012 → Jan 2020 | major depressive disorder | University Hospital, Tours | Completed | No outcome recorded |
| — | NCT01467804 Comparator | Nov 2011 → Nov 2012 | major depressive disorder | Su Rui | Unknown | No outcome recorded |
| — | NCT01488266 Comparator | Nov 2011 → Jan 2013 | major depressive disorder | Korea University | Unknown | No outcome recorded |
| — | NCT02300051 Background | Feb 2011 → Apr 2015 | sexual disorder | University of Sao Paulo General Hospital | Completed | No outcome recorded |
| — | NCT01831440 Background | Jan 2011 → Jan 2014 | depressive disorder | Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT00944996 Comparator | Jun 2009 → Jun 2010 | major depressive disorder | Tirat Carmel Mental Health Center | Completed | No outcome recorded |
| — | NCT01027559 Comparator | Feb 2009 → Jan 2014 | major depressive disorder | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT00564278 Background | Feb 2008 → Aug 2013 | depressive disorder | New York State Psychiatric Institute | Completed | No outcome recorded |
| — | NCT00421369 Background | Sep 2007 → Aug 2011 | major depressive disorder | Hadassah Medical Organization | Completed | No outcome recorded |
| — | NCT00873795 Background | Apr 2007 → Mar 2009 | major depressive disorder | Chimei Medical Center | Completed | No outcome recorded |
| — | NCT00325000 Background | Nov 2000 → Aug 2004 | major depressive disorder | German Research Foundation | Terminated | No outcome recorded |
Press releases naming this drug 20 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-09-20 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Lundbeck Receive Complete Response Letter from U.S. FDA for sNDA of REXULTI (brexpiprazole) in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)® otsuka.co.jp ↗ |
| 2025-09-20 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Lundbeck Receive Complete Response Letter from U.S. FDA for sNDA of REXULTI® (brexpiprazole) in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD) otsuka-us.com ↗ |
| 2025-07-19 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Lundbeck Issue Statement on U.S. Food and Drug Administration (FDA) Advisory Committee Meeting on REXULTI (brexpiprazole) in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD)® otsuka.co.jp ↗ |
| 2025-01-10 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Announces FDA Plans to Host an Advisory Committee Meeting to Discuss the sNDA for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD) otsuka.co.jp ↗ |
| 2025-01-10 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Announces FDA Plans to Host an Advisory Committee Meeting to Discuss the sNDA for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD) otsuka-us.com ↗ |
| 2024-12-19 | Otsuka Pharmaceutical Development & Commercialization, Inc. | JAMA Psychiatry Publishes Results of Otsuka and Lundbeck's Phase 3 Trial of Brexpiprazole in Combination with Sertraline in Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults otsuka.co.jp ↗ |
| 2024-12-18 | Otsuka Pharmaceutical Development & Commercialization, Inc. | JAMA Psychiatry Publishes Results of Otsuka and Lundbeck's Phase 3 Trial of Brexpiprazole in Combination with Sertraline in Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults otsuka-us.com ↗ |
| 2024-06-25 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Lundbeck announce FDA acceptance of sNDA filing for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD) otsuka.co.jp ↗ |
| 2024-06-25 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Lundbeck Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder (PTSD) otsuka-us.com ↗ |
| 2024-05-29 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Lundbeck Present Results from Three Clinical Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults otsuka.co.jp ↗ |
| 2024-05-28 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Lundbeck Present Results from Three Clinical Trials of Brexpiprazole in Combination with Sertraline for the Treatment of Post-Traumatic Stress Disorder (PTSD) in Adults otsuka-us.com ↗ |
| 2024-04-10 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Lundbeck submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD otsuka-us.com ↗ |
| 2024-04-09 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Lundbeck submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD otsuka.co.jp ↗ |
| 2023-09-07 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Pharmaceutical and Lundbeck Announce Topline Results from Two Phase 3 Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults otsuka.co.jp ↗ |
| 2023-09-07 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Pharmaceutical and Lundbeck Announce Topline Results from Two Phase 3 Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults otsuka-us.com ↗ |
| 2018-11-30 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka and Lundbeck report positive phase II data for the combination treatment of brexpiprazole and sertraline for the treatment of Post-Traumatic Stress Disorder (PTSD) otsuka.co.jp ↗ |
| 2017-07-28 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Otsuka Submits New Drug Application in Japan for Aripiprazole Sertraline Combination Tablets otsuka.co.jp ↗ |
| 2007-01-24 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Files Patent Infringement Complaints Regarding Sertraline Hydrochloride tevapharm.com ↗ |
| 2006-08-14 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of Generic Zoloft® tevapharm.com ↗ |
| 2006-06-30 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Receives FDA Approval for Generic Zoloft® Tablets tevapharm.com ↗ |
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 343 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sertraline | “we have restricted the IMPACT list of antidepressants to SSRIs (sertraline, escitalopram, paroxetine, fluoxetine, citalopram), duloxetine, bupropion, and mirtazapine. These...” NCT02458690 ↗331“In this study, the investigators use selective serotonin reuptake inhibitors (SSRIs, i.e., sertraline, fluoxetine and fluvoxamine)and tricyclic drugs(i.e., clomipramine)...” NCT06942494 ↗ “Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa)...” NCT01831440 ↗ “Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗ “Medication group is a control group that can choose to use the serotonin reuptake inhibitors (SSRIs) approved by China food and Drug Administration (SFDA) for the treatment of...” NCT03558256 ↗ “In cases of intolerance or adverse reaction to fluoxetine, the investigator will switch to sertraline (25 to 200mg) or escitalopram (5 to 20mg), the other two antidepressants...” NCT05002309 ↗ “Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine; sertraline;...” NCT00270959 ↗ “Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline,...” NCT01347541 ↗ “ADT such as citalopram, escitalopram, fluoxetine, sertraline, paroxetine, vilazodone, venlafaxine, desvenlafaxine, duloxetine or bupropion prescribed in accordance with its...” NCT01838876 ↗ “Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine,...” NCT02400346 ↗ “SSRI (paxil CR, es-citalopram, fluoxetine, sertraline) start with (paxil CR 12.5mg, es-citalopram 10mg, fluoxetine 20mg, sertraline 50mg) for 1 week up to maximal dosage,...” NCT01357967 ↗ “Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week...” NCT00854100 ↗ “Selective Serotonin Reuptake Inhibitor (Escitalopram, 5-10 mg in pregnancy and Sertraline, 12.5-25 mg in postpartum) and/or Benzodiazepine (Alprazolam, 0.25-0.5 mg) will be...” NCT06001021 ↗ “SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine...” NCT01436175 ↗ “The dose is 20-60mg/day for fluoxetine, 20-40mg/day for paroxetine, 100-300mg/day for fluvoxamine, 50-200mg/day for sertraline, 20-40mg/day for citalopram, 10-20mg/day for...” NCT05148169 ↗ “Participants will receive SSRI antidepressant (such as, citalopram, escitalopram, fluvoxamine, fluoxetine, paroxetine, sertraline, vilazodone or vortioxetine) as a part of...” NCT03321526 ↗ “If never taken SSRI or SNRI, commence primary medication arm (SSRI: sertraline, escitalopram or Pregabalin/SNRI: duloxetine, venlafaxine) will be described to patient and will...” NCT04478526 ↗ “Administer Toludesvenlafaxine (40-80 mg daily) or imported Sertraline (50-200 mg daily), supplemented with Lorazepam (0.4-0.8 mg) or Alprazolam (0.4-0.8 mg) as needed for sleep support.” NCT07552246 ↗ “Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.” NCT00742573 ↗ “approved by the State Food and Drug Administration (CFDA) for the treatment of OCD (i.e., fluoxetine, paroxetine, sertraline and fluvoxamine) as well as citalopram and escitalopram” NCT05528224 ↗ “SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.” NCT05832619 ↗ “quantifying the range of concentration to citalopram, escitalopram, sertraline, fluoxetine, paroxetine, fluvoxamine, duloxetine and venlafaxine in mother plasma and breast milk” NCT01796132 ↗ “This study uses SSRIs class drugs, including fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, and escitalopram, with no specific restrictions on the type of drugs.” NCT06358014 ↗ “We made other SSRIs (escitalopram, sertraline) and SNRIs (desvenlafaxine, duloxetine, venlafaxine) our third-line antidepressants, given their negligible effects on weight.” NCT04437485 ↗ “ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.” NCT01715805 ↗ “Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily” NCT01436162 ↗ “alternative treatments may include another first-line antidepressant:fluoxetine 20 mg; paroxetine up to 60 mg; sertraline up to 200 mg; bupropion up to 300 mg” NCT02178696 ↗ “SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist.” NCT05720637 ↗ “SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist.” NCT05605002 ↗ “These include fluoxetine, paroxetine, sertraline, fluvoxamine, and others, with tricyclic drugs like clomipramine and SNRIs such as venlafaxine.” NCT06659094 ↗ “This study will also evaluate the effectiveness of the SSRI sertraline plus cognitive behavioral therapy (CBT) to treat people with OCD.” NCT00382291 ↗ “primary focus will be on serotonin-reuptake inhibiting antidepressant (escitalopram 5-20mg, sertraline 50-200 mg daily) monotherapy” NCT02752542 ↗ “Sertraline, a selective serotonin reuptake inhibitor (SSRI), is one of the most commonly used antidepressant during pregnancy.” PMID 33751155 ↗ Mar 2021 “Test Product: 50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water” NCT03711708 ↗ “medication treatment will be a selective serotonin reuptake inhibitor (either fluoxetine, sertraline or escitalopram).” NCT04598230 ↗ “selective serotonin reuptake inhibitors (fluoxetine, sertraline, citalopram, escitalopram, paroxetine or fluvoxamine)” NCT03993535 ↗ “Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine).” NCT00745017 ↗ “serotonin reuptake inhibitors (fluoxetine 20 - 80 mg/day, paroxetine 20 - 60 mg/day, sertraline 50 - 200 mg/day)” NCT02300051 ↗ “Patients will begin 12 weeks of sertraline treatment initiated at a daily dose of 50 mg for the first 4 weeks.” NCT07015944 ↗ “Participants will receive selective serotonin reuptake inhibitors (SSRIs) such as Sertraline over six weeks.” NCT06955845 ↗ “Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label” NCT01838681 ↗ “a choice of 3 selective serotonin reuptake inhibitors (SSRIs; ie, sertraline, fluoxetine, or paroxetine)” PMID 41091477 ↗ Dec 2025 “The second group has administered sertralin (50mg)+ketoprofen (100mg) (Sertraline \& Ketoprofen) daily.” NCT03514810 ↗ “sertraline: 100-200mg, citalopram 20-40mg, escitalopram 10-20mg, paroxetine 20-60mg; fluoxetine 20-80mg” NCT01903447 ↗ “Adjunctive antidepressant agents: nortriptyline, duloxetine, sertraline, trazodone, or mirtazapine” NCT01943435 ↗ “50 mg/day of sertraline plus omega-3 FA or 50 mg/day of sertraline plus placebo for 10 weeks.” NCT02021669 ↗ “SSRI treated group are depressive patients treated with fluoxetine, paroxetine or sertraline” NCT01237275 ↗ “SSRI treated group is depressive patients treated with fluoxetine, paroxetine, or sertraline” NCT00817375 ↗ “AD: aripiprazole, bupropion, duloxetine, escitalopram, mirtazapine, sertraline, venlafaxine” NCT04747314 ↗ “Patients will receive the "treatment as usual" with a SSRI: sertraline or citalopram.” NCT02262156 ↗ “which included escitalopram, sertraline, and desvenlafaxine in a prescribed sequence.” PMID 27788313 ↗ Oct 2016 “Drug: Sertraline positive control Drug: Placebo placebo to Ammoxetine hydrochlorid.” NCT06827431 ↗ “Sertraline 50 mg/day or Duloxetine 60 mg/day or Bupropion XL 150-300 mg/day” NCT07654179 ↗ “fluoxetine, paroxetine, sertraline, fluvoxamine, escitalopram, clomipramine” NCT02431845 ↗ “Escitalopram, 20mg-40mg daily or Sertraline 50-150 mg daily for 12 weeks” NCT02137369 ↗ “Fluoxetine, escitalopram, citalopram, fluvoxamine, or sertraline” NCT03222570 ↗ “The treatment will start with Sertraline (SSRI) - doses of 50 mg” NCT06467474 ↗ “the other receiving an SSRI (e.g., sertraline or escitalopram)” NCT06957223 ↗ “paroxetine, fluoxetine, sertraline, escitalopram, citalopram” NCT00944996 ↗ “Sertraline (according to response, and tolerance)25-200mg” NCT01000402 ↗ “Oral sertraline administered once daily in the morning” NCT07478796 ↗ “sertraline (50 mg, increased to 100 to 150 mg)” NCT00118430 ↗ “ASC-01 (aripiprazole/sertraline combination)” NCT02046564 ↗ “fluoxetine (Prozac); sertraline (Zoloft)” NCT01460212 ↗ “escitalopram, citalopram or sertraline” NCT02279953 ↗ “sertraline hydrochloride 50-200mg/day” NCT02023567 ↗ “- Sertraline 50-200 mg/d. N06AB06” NCT01305707 ↗ “Arm 1: Sertraline (Zoloft) 50 mg” NCT00066859 ↗ “sertraline (Zoloft and others)” NCT01944657 ↗ “sertraline (Zoloft®) tablets” NCT03538691 ↗ “Sertraline (Zoloft) 25-200;” NCT00074815 ↗ “Sertraline, "Zoloft"” NCT02358343 ↗ “Sertraline (Zoloft)” NCT00797966 ↗ “Sertraline, Zoloft” NCT01916824 ↗ “sertraline_Zoloft” NCT01352572 ↗ “sertraline_Zoloft” NCT01352559 ↗ “sertraline_Zoloft” NCT00817011 ↗ “sertraline_Zoloft” NCT01228357 ↗ “Sertraline” NCT00864019 ↗ “sertraline” NCT01488266 ↗ “sertraline” NCT00157547 ↗ |
| Known as | Aremis | ChEMBL registry synonym — accepted as the source's own label CHEMBL809 ↗ |
| Known as | Besitron | ChEMBL registry synonym — accepted as the source's own label CHEMBL809 ↗ |
| Known as | CP-51,974-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL809 ↗ |
| Known as | Lustral | “Sertraline hydrochloride (trade names Zoloft, Lustral) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.” NCT01856127 ↗ |
| Known as | NSC-746308 | ChEMBL registry synonym — accepted as the source's own label CHEMBL809 ↗ |
| Known as | NSC-758948 | ChEMBL registry synonym — accepted as the source's own label CHEMBL809 ↗ |
| Known as | SER | “The purpose of this study is to compare 3 treatments for children with OCD: medication (sertraline, SER) alone vs OCD-specific therapy (Cognitive Behavior Therapy, CBT) vs...” NCT00000384 ↗ |
| Known as | Sertralin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00433121 ↗ |
| Known as | Sertralina | ChEMBL registry synonym — accepted as the source's own label CHEMBL809 ↗ |
| Known as | Sertraline (as hydrochloride) | ChEMBL registry synonym — accepted as the source's own label CHEMBL809 ↗ |
| Known as | Sertraline HCl | “Sertraline HCl 100 mg tablets, single dose” NCT00864344 ↗ |
| Known as | sertraline hydrochloride | “This study is designed to determine differences in drug exposure in subjects after being administered 50 mg tablets of sertraline hydrochloride as compared to drug exposure...” NCT01235195 ↗7“The objective of this study was to investigate the bioequivalence of Mylan's sertraline hydrochloride 100 mg tablets to Pfizer's Zoloft® 100 mg tablets following a single, oral...” NCT00648856 ↗ “Sertraline hydrochloride is a selective serotonin reuptake inhibitor which established improvement in itching in patients with cholestatic pruritis.” NCT05341843 ↗ “Sertraline hydrochloride (trade names Zoloft, Lustral) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.” NCT01856127 ↗ “Sertraline hydrochloride 100 mg tablets (test) versus Zoloft® (reference)” NCT00836849 ↗ “Sertraline hydrochloride 100 mg tablets (test) versus Zoloft® (reference)” NCT00836667 ↗ “Sertraline Hydrochloride Tablets 100 mg” NCT00650325 ↗ |
| Known as | Sertraline, Zoloft | “Sertraline, "Zoloft"” NCT02358343 ↗3“sertraline (Zoloft)” NCT01460212 ↗ “Sertraline, Zoloft” NCT01916824 ↗ “sertraline, zoloft” NCT01114100 ↗ |
| Known as | SRT | “sertraline (SRT), cognitive behavioral therapy” PMID 22122292 ↗ Dec 20111“sertraline (SRT, n = 133)” PMID 25721183 ↗ Dec 2014 |
| Known as | Zoloft | “Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa)...” NCT01831440 ↗37“Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR),...” NCT00564278 ↗ “The objective of this study was to investigate the bioequivalence of Mylan's sertraline hydrochloride 100 mg tablets to Pfizer's Zoloft® 100 mg tablets following a single, oral...” NCT00648856 ↗ “The purpose of this study is to document the efficacy of sertraline (Zoloft) in the treatment of depression (major depressive disorder) after TBI, including the impact on...” NCT00233103 ↗ “The purpose of this study is to understand changes in brain chemical signals when people take antidepressants called sertraline (Zoloft®) and bupropion (Wellbutrin SR, Zyban ®).” NCT00178828 ↗ “The purpose of the study is to evaluate the efficacy and safety of flexible doses of escitalopram (Lexapro) compared to sertraline (Zoloft) for treatment of Dysthymic Disorder.” NCT00234312 ↗ “in fluoxetine (Prozac)-resistant adolescents with Major Depressive Disorder (MDD), Lamotrigine plus fluoxetine will be safe and as effective as sertraline (Zoloft).” NCT00284791 ↗ “the efficacy of the serotonergic medication sertraline (Zoloft) in the treatment and prevention of posttraumatic psychiatric sequelae in ASD victims.” NCT00050804 ↗ “Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,” NCT01962753 ↗ “Patients are assigned randomly (like tossing a coin) to receive St. John's wort, Sertraline (Zoloft), or a placebo (sugar pill) for 8 weeks.” NCT00005013 ↗ “This study is a control trial of sertraline (Zoloft) in children aged 2 to 5 years old inclusive with Autism Spectrum Disorder.” NCT02385799 ↗ “administer/prescribe the common antidepressant medication, sertraline (tradename Zoloft), track symptom response over time” NCT05892744 ↗ “examine the effectiveness of the FDA-approved medication sertraline (Zoloft) for major depression.” NCT00177996 ↗ “To study the effectiveness of sertraline (Zoloft) in treating depression in adults with diabetes.” NCT00374426 ↗ “All qualified participants will be started on sertraline (Zoloft) for eight weeks.” NCT00133822 ↗ “Sertraline (Zoloft) works as a selective serotonin reuptake inhibitor (SSRI).” NCT00001483 ↗ “adding sertraline (Zoloft®) to Trauma-Focused Cognitive Behavioral Therapy” NCT00078767 ↗ “Sertraline (Zoloft), daily, for 16 weeks.” NCT00302068 ↗ “Zoloft® 100 mg tablets, single dose” NCT00864344 ↗ “sertraline (Zoloft and others)” NCT01944657 ↗ “sertraline (Zoloft®) tablets” NCT03538691 ↗ “Sertraline (Zoloft) 25-200;” NCT00074815 ↗ “Sertraline [Zoloft]” NCT00009191 ↗ “Sertraline (Zoloft)” NCT00208117 ↗ “sertraline (Zoloft)” NCT00000458 ↗ “Sertraline (Zoloft)” NCT00797966 ↗ “sertraline (Zoloft)” NCT00000446 ↗ “Sertraline (Zoloft)” NCT00331305 ↗ “sertraline (Zoloft)” NCT00000440 ↗ “sertraline (Zoloft)” NCT00229476 ↗ “sertraline (Zoloft)” NCT00179257 ↗ “Sertraline (Zoloft)” NCT00086138 ↗ “sertraline (Zoloft)” NCT00004554 ↗ “sertraline_Zoloft” NCT00817011 ↗ |
| Known as | Zoloft (Registered) | “A Phase 1, Single Center Randomized, Three-way Crossover, Double-blinded, Placebo- And Moxifloxacin-controlled Thorough Qt (Tqt) Study To Determine The Effects Of Sertraline...” NCT02651623 ↗ |
| Known as | Zoloft Oral Solution | “Test Product: 50 mg sertraline administered as 2.5 mL of Zoloft Oral Solution (20 mg/mL) after dilution with 120 mL of water” NCT03711708 ↗ |
| Action | Inhibit | “acts centrally to selectively block serotonin uptake” NCT00001777 ↗1“Serotonin transporter inhibitor” CHEMBL809 ↗ |
| Modality | Small molecule | “Selective Serotonin Reuptake Inhibitor” NCT00043550 ↗ |
| Route | Oral | “FLD patients will undergo a controlled clinical trial of an orally administered serotonergic agent (Sertraline)” NCT00001777 ↗ |
| Target | SLC6A4 | “Serotonin transporter inhibitor” CHEMBL809 ↗ |